Table 1 Population characteristics
Characteristics | Total population (n = 282) | Progression group (n = 20) | Progression-free group (n = 262) |
|---|---|---|---|
Clinical risk group | Low: 197 (69.8%) | Low: 9 (45%) | Low: 188 (71%) |
Intermediate: 83 (29.4%) | Intermediate: 10 (50%) | Intermediate: 73 (27.9%) | |
Favorable intermediate: 67 (23%) | Favorable intermediate: 8 (40%) | Favorable intermediate: 59 (22%) | |
Unfavorable intermediate: 16 (5.6%) | Unfavorable intermediate: 2 (10%) | Unfavorable intermediate: 14 (5%) | |
High: 1 (0.3%) | High: 0 | High: 1 (0.3%) | |
NA: 1 | NA: 1 | Â | |
Radiological risk group | Low: 158 (56%) | Low: 9 (45%) | Low: 150 (57.3%) |
Intermediate: 84 (29.7%) | Intermediate: 10 (50%) | Intermediate: 75 (28.6%) | |
Favorable intermediate: 67 (23.7%) | Favorable intermediate: 8 (40%) | Favorable intermediate: 60 (22.9%) | |
Unfavorable intermediate: 17 (6%) | Unfavorable intermediate: 2 (10%) | Unfavorable intermediate: 15 (5.7%) | |
High: 33 (11.7%) | High: 0 | High: 31 (11.8%) | |
NA: 7 | NA: 1 | NA: 6 | |
Clinical Tumor stage | T1c: 226 (80%) | T1c: 15 (75%) | T1c: 211 (80.5%) |
T2a: 50 (17.7%) | T2a: 3 (15%) | T2a: 47 (17.9%) | |
T2b: 4 (1.4%) | T2b: 1 (5%) | T2b: 3 (1.1%) | |
T2c: 1 (0.3%) | T2c: 0 | T2c: 1 (0.3%) | |
NA: 1 | NA: 1 | Â | |
Radiological Tumor stage | T1c: 98 (34.7%) | T1c: 5 (25%) | T1c: 93 (35.5%) |
T2a: 124 (44%) | T2a: 10 (50%) | T2a: 114 (43.5%) | |
T2b: 20 (7.1%) | T2b: 2 (10%) | T2b: 18 (6.9%) | |
T2c: 32 (11.3%) | T2c: 2 (10%) | T2c: 30 (11.5%) | |
T 3a: 1 (0.3%) | T 3a: 0 | T3a: 1 (0.3%) | |
NA: 7 | NA: 1 | NA: 6 | |
Gleason score | 4: 2 (0.7%) | 4: 0 | 4: 2 (0.8%) |
5: 7 (2.5%) | 5: 1 (5%) | 5: 6 (2.3%) | |
6: 213 (75.5%) | 6: 11 (55%) | 6: 202 (77.1%) | |
7 (3 + 4): 52 (18.4%) | 7 (3 + 4): 7 (35%) | 7 (3 + 4): 45 (17.2%) | |
7 (4 + 3): 8 (2.8%) | 7 (4 + 3): 1 (5%) | 7 (4 + 3): 7 (2.7%) | |
Pre-treatment PSA serum level | 6.4 ng/mL [0.9–17] | 6.6 [3.76–11.9] | 6.4 [0.9–17] |
Cytoreductive hormone therapy | Yes: 131 (46.4%) | Yes: 12 (60%) | Yes: 119 (45.4%) |
No: 148 (52.4%) | No: 8 (40%) | No: 140 (53.4%) | |
NA: 3 | Â | NA: 3 | |
Duration of cytoreductive hormone therapy | 3 months [0.5–12] | 2 months [1–8] | 3 months [0.5–12] |
Location of positive biopsy cores | Base: 145 (51.4%) | Base: 11 (55%) | Base: 134 (51.1%) |
Midgland: 149 (52.8%) | Midgland: 10 (50%) | Midgland: 139 (53.1%) | |
Apex: 131 (46.5%) | Apex: 10 (50%) | Apex: 121 (46.2%) | |
NA: 37 | NA: 3 | NA: 34 | |
Percentage of positive biopsy cores | Median: 17% | Median: 17% | Median: 17% |
<  50%: 262 (92.3%) | <  50%: 17 (92.3%) | <  50%: 245 (93.5%) | |
≥ 50%: 14 (4.9%) | ≥ 50%: 3 (4.9%) | ≥ 50%: 11 (4.2%) | |
NA: 6 | NA: 0 | NA: 6 | |
Radiological location of tumor | None: 90 (31.9%) | None: 5 (25%) | None: 85 (32.4%) |
Base: 72 (25.5%) | Base: 8 (40%) | Base: 64 (24.4%) | |
Midgland: 112 (39.7%) | Midgland: 11 (55%) | Midgland: 101 (38.5%) | |
Apex: 63 (22.3%) | Apex: 6 (30%) | Apex: 57 (21.8%) | |
NA: 16 | NA: 1 | NA: 15 | |
Disease relapse | Yes: 20 (7.1%) | Â | Â |
No: 262 (92.9%) | Â | Â | |
Death | Yes: 2 (0.7%) | Yes: 0 | Yes: 2 (0.7%) |
No: 280 (99%), | No: 20 | No: 260 (99%) | |
Median D90 (Gy) | 181 [153–189] | 181 [171–189] | 181 [153–189] |
Median V100 (%) | 100 [99–100] | 100 [99,7–100] | 100 [99–100] |
Median V150 (%) | 49.2 [31.5–64.8] | 49.2 [33–55] | 49.2[31–65] |
Median D10% urethra | 196.5 [168.6–240] | 200 [182–226] | 196 [168–240] |
Median D30% urethra | 183[102.9–212.2] | 183 [165–205] | 182.9 [102–212] |